Therapy for nifedipine-induced gingival overgrowth by Saireito in rats

Toshimi Hattori, K. Nakano, T. Kawakami, A. Tamura, T. Ara, P. L. Wang

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objective: A calcium antagonist, nifedipine, causes gingival overgrowth as a side effect. It has been confirmed that the Japanese traditional medicine, Saireito, inhibits the nifedipine-induced proliferation of gingival fibroblasts in vitro. We performed an in vivo experiment to determine whether Saireito has a therapeutic use in the treatment of nifedipine-induced gingival overgrowth. Methods: The rats had significant gingival overgrowth induced by the administration of nifedipine. The space between the submandibular incisors and the width of buccal gingiva of maxillary left first molar were macroscopically measured. The buccal gingiva was microscopically examined. Results: Eight weeks after Saireito was administrated together with nifedipine, Saireito decreased both the incisor space and the gingiva width which had been enlarged by nifedipine and furthermore, the area of connective tissue of nifedipine + Saireito group was significantly smaller than that of nifedipine alone. Conclusion: In conclusion, Saireito may be clinically effective in therapy for calcium antagonist-induced gingival overgrowth.

Original languageEnglish
Pages (from-to)497-501
Number of pages5
JournalEuropean journal of medical research
Volume14
Issue number11
Publication statusPublished - Dec 24 2009
Externally publishedYes

Keywords

  • Gingival overgrowth
  • Nifedipine
  • Rat
  • Saireito
  • Therapy

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Therapy for nifedipine-induced gingival overgrowth by Saireito in rats'. Together they form a unique fingerprint.

  • Cite this

    Hattori, T., Nakano, K., Kawakami, T., Tamura, A., Ara, T., & Wang, P. L. (2009). Therapy for nifedipine-induced gingival overgrowth by Saireito in rats. European journal of medical research, 14(11), 497-501.